Clinical trials: Classic Hodgkin Lymphoma
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.
This phase II trial studies how well combination chemotherapy with or without bortezomib works in treating patients with classical Hodgkin lymphoma that has come back or does not respond to prior treatment.
- Trial name
- NCT00967369
- Testing
- Bortezomib, Carboplatin, Etoposide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Classic Hodgkin Lymphoma
Liposomal Doxorubicin-containing Front-line Treatment in Elderly Patients With HL (HL-MVD)
Study on the use of a polychemotherapy scheme based on liposomal doxorubicin, vinblastine and dacarbazine (MVD) as first line in the therapy of elderly patients affected by classic Hodgkin lymphoma
- Trial name
- NCT06235047
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Federico II University
Hodgkin Disease
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with…
- Trial name
- CheckMate 744 (NCT02927769)
- Testing
- Nivolumab, brentuximab vedotin, bendamustine
- Where
- 79 sites in United States, Canada and 9 more
- Volunteers
- 72 people
- Sponsor
- Bristol-Myers Squibb
Lymphoma, Lymphoproliferative Disorder
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment
RATIONALE: KX2-391 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of KX2-391 in treating patients with advanced…
- Conditions
- Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00646139
- Testing
- Src kinase inhibitor KX2-391, immunoenzyme technique, pharmacological study
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Roswell Park Cancer Institute
Hodgkin's Lymphoma
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
Objectives: Primary objective: Phase-I: To determine the maximal tolerated dose (MTD) of panobinostat (LBH589) + Ifosfamide + Mesna, Carboplatin and Etoposide (ICE) combination Randomized Phase-II: To estimate the complete…
- Trial name
- NCT01169636
- Testing
- Panobinostat, Ifosfamide, Mesna
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
This is a two-part, Phase 2, multicenter, open-label, single arm study to evaluate the safety and efficacy of autologous CD30.CAR-T in adult and pediatric subjects with relapsed or refractory CD30+ classical Hodgkin Lymphoma.
- Conditions
- Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric
- Trial name
- NCT04268706
- Testing
- CD30.CAR-T, Fludarabine, Bendamustine
- Where
- 5 sites in United States
- Volunteers
- 97 people
- Sponsor
- Tessa Therapeutics
Classical Hodgkin Lymphoma
CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma
Patients with relapsed low-risk CD30 classical Hodgkin Lymphoma will have autologous CD30 CAR T-cell manufactured. Dose escalation will be used to determine the RP2D. Following lymphodepletion, CAR T-cell will be infused.
- Trial name
- REACH-CD30 (NCT07575893)
- Testing
- CD30+ CAR T-cells, Bendamustin, Fludarabine
- Volunteers
- 12 people
- Sponsor
- New York Medical College
Hodgkin Lymphoma
Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.
This is a retrospective, monocenter and non-interventional study. Data were retrospectively collected from all patients who completed the BV-Bs scheme in the time period between 1 September 2013 and 1 September 2023.
- Trial name
- HL_PR/R-B (NCT06295211)
- Testing
- observational
- Volunteers
- 32 people
- Sponsor
- Federico II University
Hodgkin Lymphoma
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment.
- Trial name
- NCT03755804
- Testing
- bendamustine, Etoposide, Doxorubicin
- Where
- 8 sites in United States
- Volunteers
- 232 people
- Sponsor
- St. Jude Children's Research Hospital
Classical Hodgkin Lymphoma Relapsed
Study of Bendamustine, Gemcitabine and Vinorelbine Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma
The goal of this phase III clinical trial was to make a direct head to head comparison between the chemotherapeutics; Bendamustine, Gemcitabine and Vinorelbine (BEGEV) and the the Gemcitabine, Dexamethasone and Cisplatin (GDP)…
- Trial name
- BEGEV (NCT07450508)
- Testing
- BEGEV (Bendamustine, Gemcitabine,Vinorelbine), GDP(Gemcitabine, Dexamethasone and Cisplatin)
- Where
- Egypt
- Volunteers
- 88 people
- Sponsor
- Cairo University
Grade III and IV Hemorrhoids
Haemorrhoidectomy With vs Without Lateral Internal Sphincterotomy
Hemorrhoids are a common anorectal condition that often require surgical treatment in advanced stages. Open hemorrhoidectomy is effective but is frequently associated with significant postoperative pain and early bleeding.
- Trial name
- NCT07360912
- Testing
- Hemorrhoidectomy With LIS, Conventional Hemorrhoidectomy
- Where
- Iraq
- Volunteers
- 120 people
- Sponsor
- University of Baghdad
Hodgkin Lymphoma
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.
- Trial name
- NCT05180097
- Testing
- Gemcitabine, Dexamethasone, Cisplatin
- Where
- 18 sites in Australia, Canada
- Volunteers
- 84 people
- Sponsor
- Canadian Cancer Trials Group
Hodgkin Lymphoma, Adult
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma
- Trial name
- NCT06984146
- Testing
- Nivolumab, Doxorubicin, Vinblastine
- Where
- Russia
- Volunteers
- 54 people
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of gemcitabine, bendamustine, and nivolumab when given together and to see how well they work in treating patients with classic Hodgkin lymphoma that has come back or…
- Conditions
- Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Hodgkin Lymphoma
- Trial name
- NCT03739619
- Testing
- Bendamustine, Gemcitabine, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Emory University
Relapsed Classic Hodgkin Lymphoma
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment…
- Trial name
- NCT04561206
- Testing
- Brentuximab Vedotin, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Hodgkin Lymphoma
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
The Purpose of this trial is: to determine complete response rate (CRR) after six cycles of chemotherapy to determine complete remission rate (CR/CRr) as final treatment outcome after completion of treatment
- Trial name
- NCT01569204
- Testing
- Etoposide, Cyclophosphamide, Doxorubicin
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University of Cologne
Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
This phase III trial studies brentuximab vedotin and combination chemotherapy to see how well they work compared to combination chemotherapy alone in treating children and young adults with stage IIB with bulk, stage IIIB, IVA…
- Conditions
- Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma
- Trial name
- NCT02166463
- Testing
- Bleomycin Sulfate, Brentuximab Vedotin, Cyclophosphamide
- Where
- 199 sites in United States, Canada and 1 more
- Volunteers
- 600 people
- Sponsor
- National Cancer Institute (NCI)
Classic Hodgkin Lymphoma
Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
This study is conducted to evaluate the safety and efficiency of Penpulimab combined with AVD in patients with newly- diagnosed advanced classic Hodgkin lymphoma.
- Trial name
- NCT05949931
- Testing
- Concurrent penpulimab and AVD, Sequential penpulimab and AVD
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Sun Yat-sen University
Hodgkin Lymphoma
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
The purpose of this study is to evaluate pembrolizumab (MK-3475) in the treatment of participants with relapsed or refractory Classical Hodgkin Lymphoma.
- Trial name
- NCT02684292
- Testing
- pembrolizumab, brentuximab vedotin
- Volunteers
- 304 people
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of ipilimumab and nivolumab when given together with brentuximab vedotin, and how well they work in treating patients with Hodgkin lymphoma that has returned after a…
- Trial name
- NCT01896999
- Testing
- Biopsy Procedure, Biospecimen Collection, Brentuximab Vedotin
- Where
- 479 sites in United States
- Volunteers
- 146 people
- Sponsor
- National Cancer Institute (NCI)